IFNA17 and breast carcinoma: Neuroblastoma BE(2)-C, breast cancer MCF-7, and normal lung fibroblast MRC-5 cells were treated with control, 0.5 μM SAHA, 500 IU/ml INFα or SAHA plus INFα for 3 days.